AlgoTherapeutix
Signal active
Organization
Contact Information
Overview
AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy and adapting treatment to the very particular needs of the people afflicted. ATX01's admission into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy has been approved by the FDA. In the meanwhile, AlgoTx is investigating its potential in erythromelalgia, a rare and painful condition.
About
Industries
Information Technology, Biotechnology, Pharmaceutical
Founded
2018
Employees
1-10
Headquarters locations
Europe
Social
N/A
Profile Resume
AlgoTherapeutix headquartered in Europe, operates in the Information Technology, Biotechnology, Pharmaceutical sector. The company focuses on Information Technology and has secured $1.8B in funding across 48 round(s). With a team of 1-10 employees, AlgoTherapeutix is actively contributing to advancements in Information Technology. Their latest funding round, Grant - AlgoTherapeutix, raised $1.1M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
4
Investors
1
Lead Investors
0
Total Funding Amount
$37.4M
Details
3
AlgoTherapeutix has raised a total of $37.4M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 12.0M | ||
| 2019 | Seed | 2.9M | ||
| 2023 | Early Stage Venture | 21.5M |
Investors
AlgoTherapeutix is funded by 17 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| AlgoTherapeutix | - | FUNDING ROUND - AlgoTherapeutix | 21.5M |
| Omnes Capital | - | FUNDING ROUND - Omnes Capital | 21.5M |
| AlgoTherapeutix | - | FUNDING ROUND - AlgoTherapeutix | 1.1M |
| Bpifrance | - | FUNDING ROUND - Bpifrance | 1.1M |
Recent Activity
There is no recent news or activity for this profile.